Skip to main content

Biogen delays 'complex and unpredecented' Alzheimer’s drug application

Biogen previously said it expected to ask the FDA to approve its Alzheimer's drug aducanumab in “early 2020”.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.